

CLAIMS

sub B1
1. A method of altering the immunoreactivity of human cells, which method comprising introducing a gene
5 encoding an accessory molecule ligand into said cells so that said accessory molecule ligand is expressed on the surface of said cells.

2. The method of claim 1 wherein the accessory molecule to which the accessory molecule ligand
10 specifically binds is also present on the surface of said human cells.

3. The method of claim 1 wherein said human cells are neoplastic human cells.

4. The method of claim 1 wherein said accessory
15 molecule ligand gene is a chimeric gene.

5. The method in claim 1 wherein said accessory molecule ligand gene is present in a vector capable of transducing human cells.

6. The method of claim 1 wherein said accessory
20 molecule ligand gene is present as part of a genetic vector.

7. The method of claim 1 wherein said accessory molecule ligand gene is operatively linked to a promoter region and a polyadenylation signal.

8. The method of claim 1 wherein said gene is a CD40
25 ligand gene.

9. The method of claim 7 wherein said CD40 ligand gene is a murine CD40 ligand gene.

10. The method of claim 4 wherein said gene is a
30 chimeric gene which comprises at least a portion of a murine CD40 ligand gene.

11. A method of treating a human neoplasia comprising inserting into said human neoplastic cells a gene which

12. The method of claim 11 further comprising:

b) infusing said human neoplastic cells after having inserted said accessory molecule ligand on the surface of said cells back into said patient.

14. The method of claim 11 wherein said accessory molecule ligand gene is a chimeric gene.

15. The method of claim 11 wherein said accessory molecule ligand gene is a chimeric gene which contains at least a portion of the murine CD40 ligand gene.

16. The method of claim 11 wherein said accessory
20 molecule ligand gene is present as part of a genetic
vector.

17. The method of claim 11 wherein said accessory molecule ligand gene is operatively linked to a promoter region and a 3' end region.

25 18. The method of claim 11 wherein said accessory
molecule ligand gene is a CD40 ligand gene.

19. The method of claim 11 wherein the said CD40 ligand gene is a murine CD40 ligand gene.

20. The method of claim 11 wherein said accessory
30 molecule ligand gene is a Fas-ligand gene or a CD27 ligand
gene.

21. The method of claim 11 wherein said accessory molecule ligand gene is present in a gene therapy vector.

33. The gene therapy vector of claim 23 wherein said vector is capable of transducing human cells.

34. The gene therapy vector of claim 23 wherein said vector is capable of transducing animal cells.

5 35. The gene therapy vector of claim 23 wherein said human cells are human neoplastic cells.

36. The gene therapy vector of claim 23 wherein said human cells are human antigen presenting cells.

10 37. A genetic construct containing a promoter operatively linked to an accessory molecule ligand gene which is also operatively linked to a polyadenylation signal.

38. A genetic construct in which a promoter is operatively linked to a chimeric accessory molecule ligand gene and a polyadenylation signal.

15 39. A gene therapy vector containing a chimeric accessory molecule ligand gene.

40. The gene therapy vector of claim 39 wherein said chimeric accessory molecule ligand gene contains at least one gene segment derived from a murine CD40 ligand gene and other gene segments derived from other accessory molecule genes.

41. The gene therapy vector of claim 39 wherein said other accessory molecule ligand genes are human accessory molecule ligand genes.

42. The gene therapy vector of claim 39 wherein said human accessory molecule ligand genes are human CD40 ligand genes

43. A human cell containing the gene therapy vector of claims 23-36 or 39-42 or the genetic construct of claims 37-38.

44. The human cell of claim 43 wherein said cell is an antigen presenting cell.

45. The human cell of claim 43 wherein said human cell is a neoplastic cell.

46. The human cell of claim 43 wherein said cell is an accessory cell.

5 47. An animal cell containing the gene therapy vector or genetic construct of claims 23-43.

48. An insect cell containing the gene therapy vector or genetic construct of claims 23-43.

10 49. A bacterial cell containing the gene therapy vector or genetic construct of claims 23-43.

50. A method of vaccinating an animal against a predetermined organism comprising: administering into an animal to be immunized against a predetermined organism, a vaccine comprising immunogenic antigens capable of causing
15 an immune response to said predetermined organism together with a vector containing a gene including an accessory molecule ligand.

51. The method of claim 50 wherein said immunogenic antigens are encoded by genes present on a genetic vector.

20 52. The method of claim 50 wherein said gene is a chimeric gene.

53. The method of claim 50 wherein said chimeric gene contains at least a portion of a murine CD40 ligand gene.

25 54. The method of claim 50 wherein said chimeric gene contains at least a segment of a murine CD40 ligand gene and at least a segment of a different accessory molecule gene.

55. The method of claim 50 wherein said predetermined organism is a virus, a bacteria, a fungus or a neoplastic
30 cell.

56. A method of producing an immune response directed to a predetermined antigen comprising: administering to said animal a genetic vector containing a gene encoding the

antigen to which said immune response is desired together with a genetic vector containing a gene encoding an accessory molecule ligand gene.

57. A chimeric accessory molecule ligand gene
5 comprising at least one domain or sub-domain gene segment derived from a first accessory molecule ligand gene operatively linked to the domain or sub-domain gene segment of a second accessory molecule ligand gene.

58. The chimeric accessory molecule ligand gene of
10 claim 57 in which said first and second accessory molecule ligand genes are selected from the group consisting of the genes from any species encoding a member of the tumor necrosis family, CD40-ligand, Fas-ligand, CD70, TNF α , TNF β , CD30 ligand, 4-1BB ligand (4-1BBL), TNF-related apoptosis
15 inducing ligand (TRAIL) and nerve growth factor.

59. The chimeric accessory molecule ligand gene of claim 57 in which at least one of said domain or sub-domain gene segments is an artificial gene segment.

60. The chimeric accessory molecule encoded by the
20 genes of claims 57-59.

61. A chimeric accessory molecule ligand gene comprising at least a portion of the gene encoding Domains I and II derived from an accessory molecule ligand operatively linked to at least a portion of the gene
25 encoding a Domain of an accessory molecule ligand which in turn is operatively linked to at least a portion of the gene encoding Domain IV of an accessory molecule ligand.

62. The chimeric accessory molecule ligand gene of claim 61 wherein said Domains I and II are derived from the
30 human CD40 ligand gene.

63. The chimeric accessory molecule ligand gene of claim 61 wherein said Domain IV is the human Fas-ligand Domain IV.

65. The chimeric accessory molecule ligand gene of claim 61 wherein said Domain is a domain from the same accessory molecule ligand.

67. The method of claim 4 wherein said chimeric gene
10 is a gene of claims 57-60.

69. The gene therapy vector of claim 23 wherein said
15 chimeric gene is a chimeric accessory molecule ligand gene
of claims 57-60.

70. A method of treating rheumatoid arthritis in a joint comprising inserting into the joint a vector containing a gene which encodes an accessory molecule ligand so that said accessory molecule ligand is expressed on the surface of cells within the joint.

71. The method of claim 70 wherein said accessory molecule ligand gene is a chimeric accessory molecule ligand gene which is comprised of at least a portion of a human Fas-ligand gene.

72. The method of claim 70 wherein said accessory molecule ligand gene is a chimeric accessory molecule ligand gene which contains at least a portion of the murine Fas-ligand gene.

30 73. The method of claim 70 wherein said accessory
molecule ligand gene is a murine Fas-ligand gene.

74. The method of claim 70 wherein said accessory molecule ligand gene is the murine Fas-ligand gene.

[illegible]

75. The method of claim 70 wherein said accessory molecule ligand gene is a chimeric accessory molecule gene comprised of at least a portion of domain III from the murine Fas-ligand gene and a portion of domain IV from the human Fas-ligand gene.

76. The method of claim 70 wherein said accessory molecule ligand gene is a chimeric accessory molecule ligand gene comprised of a portion of domain III of the human CD70 gene and at least a portion of domain IV of the human Fas-ligand gene.

77. A method of treating rheumatoid arthritis in a joint comprising inserting into the joint cells which have been transformed with a gene which encodes on accessory molecule ligand which is expressed on the surface of said cells.

78. A chimeric accessory molecule ligand comprised of at least a portion of the fourth domain of human Fas-ligand.

79. A chimeric accessory molecule ligand derived from a Fas-ligand in which at least one matrix metalloproteinase cleavage site has been removed.

80. A chimeric accessory molecule ligand comprised of domain III of the Murine Fas-ligand or the human CD70 gene, and domain IV of the human Fas-ligand.

81. A gene therapy vector containing a gene encoding chimeric accessory molecule of claims 78-80.

82. A cell containing a gene therapy vector of claim 81.

83. A method of altering the immunoreactivity of human cells, which method comprising introducing a gene encoding an accessory molecule ligand which has a stabilized activity into said cells so that said accessory molecule ligand is expressed on the surface of said cells.

And
B2

Add
F11

Add
B3

Add C1

Add E2